Weekly Analysts’ Ratings Updates for GlaxoSmithKline (GSK)

Several brokerages have updated their recommendations and price targets on shares of GlaxoSmithKline (LON: GSK) in the last few weeks:

  • 3/14/2019 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.
  • 3/11/2019 – GlaxoSmithKline had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 1,650 ($21.56) price target on the stock.
  • 3/11/2019 – GlaxoSmithKline had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 3/8/2019 – GlaxoSmithKline was downgraded by analysts at Shore Capital from a “buy” rating to a “hold” rating.
  • 3/8/2019 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 2/22/2019 – GlaxoSmithKline was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a GBX 1,650 ($21.56) price target on the stock, down previously from GBX 1,700 ($22.21).
  • 2/12/2019 – GlaxoSmithKline was given a new GBX 1,520 ($19.86) price target on by analysts at Deutsche Bank AG. They now have a “neutral” rating on the stock.
  • 2/8/2019 – GlaxoSmithKline had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 2/7/2019 – GlaxoSmithKline was given a new GBX 1,440 ($18.82) price target on by analysts at Kepler Capital Markets. They now have a “neutral” rating on the stock.
  • 2/7/2019 – GlaxoSmithKline was given a new GBX 1,600 ($20.91) price target on by analysts at Credit Suisse Group AG. They now have a “neutral” rating on the stock.
  • 2/7/2019 – GlaxoSmithKline had its price target raised by analysts at HSBC Holdings plc from GBX 1,820 ($23.78) to GBX 1,860 ($24.30). They now have a “buy” rating on the stock.
  • 2/7/2019 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 1,700 ($22.21) price target on the stock.
  • 2/6/2019 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,520 ($19.86) price target on the stock.
  • 2/6/2019 – GlaxoSmithKline was given a new GBX 1,900 ($24.83) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock.
  • 1/31/2019 – GlaxoSmithKline was given a new GBX 1,750 ($22.87) price target on by analysts at Jefferies Financial Group Inc. They now have a “buy” rating on the stock.
  • 1/31/2019 – GlaxoSmithKline was given a new GBX 1,900 ($24.83) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock.
  • 1/25/2019 – GlaxoSmithKline was given a new GBX 1,820 ($23.78) price target on by analysts at HSBC Holdings plc. They now have a “buy” rating on the stock.
  • 1/21/2019 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 1,510 ($19.73) price target on the stock.
  • 1/21/2019 – GlaxoSmithKline had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 1/18/2019 – GlaxoSmithKline was downgraded by analysts at Shore Capital to a “hold” rating.
  • 1/15/2019 – GlaxoSmithKline had its “equal weight” rating reaffirmed by analysts at Barclays PLC.
  • 1/14/2019 – GlaxoSmithKline had its “hold” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 1,520 ($19.86) price target on the stock.

Shares of GlaxoSmithKline stock opened at GBX 1,508.80 ($19.72) on Friday. GlaxoSmithKline plc has a 52-week low of GBX 1,235.20 ($16.14) and a 52-week high of GBX 1,724.50 ($22.53).

The company also recently declared a dividend, which will be paid on Thursday, April 11th. Stockholders of record on Thursday, February 21st will be issued a dividend of GBX 23 ($0.30) per share. This represents a dividend yield of 1.49%. This is a positive change from GlaxoSmithKline’s previous dividend of $19.00. The ex-dividend date is Thursday, February 21st.

In related news, insider Emma Walmsley sold 66,159 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of GBX 1,585 ($20.71), for a total value of £1,048,620.15 ($1,370,207.96). Also, insider Jesse Goodman acquired 845 shares of the business’s stock in a transaction that occurred on Wednesday, February 6th. The stock was bought at an average cost of GBX 1,964 ($25.66) per share, for a total transaction of £16,595.80 ($21,685.35). Over the last quarter, insiders have bought 3,881 shares of company stock valued at $6,356,144.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply